Deletions in cancer are typically identified using advanced genomic technologies such as next-generation sequencing (NGS) and comparative genomic hybridization (CGH). These techniques allow researchers to detect even small deletions that might be missed by traditional methods. NGS, in particular, provides a comprehensive view of the genomic landscape, enabling the detection of deletions across the entire genome.
